<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00153946</url>
  </required_header>
  <id_info>
    <org_study_id>EAST</org_study_id>
    <nct_id>NCT00153946</nct_id>
  </id_info>
  <brief_title>Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke</brief_title>
  <acronym>EAST</acronym>
  <official_title>Multicenter Randomized Open-Label Comparison Study on the Efficacy and Safety of Argatroban Monotherapy With Argatroban-Edaravone Combination Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Combination Therapy for Acute Ischemic Stroke Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japan Cardiovascular Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Combination Therapy for Acute Ischemic Stroke Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a
      selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and
      have frequently been used for the treatment of acute brain infarction in Japan. The effect of
      combination therapy of these drugs, however, has not yet been elucidated. This study will
      test the safety and efficacy of the combination therapy with these agents in patients with
      acute non-cardioembolic and non-lacunar ischemic stroke.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale (MRS) score</measure>
    <time_frame>at 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptomatic intracranial hemorrhage</measure>
    <time_frame>for the initial 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIHSS score, JSS score, Barthel Index, modified Rankin Scale score</measure>
    <time_frame>at various time-points</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Various adverse effects</measure>
    <time_frame>for the 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">814</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients who are allocated to Argatroban monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients who are allocated to Edaravone-Argatroban combination therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edaravone</intervention_name>
    <description>30mg/20mL vial, twice per day, not longer than two weeks</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute ischemic stroke &lt; 24 hours of onset

          -  Measurable neurological deficits caused by the present attack, ranging from 1 to 22 of
             NIHSS score on admission

        Exclusion Criteria:

          -  Definite or possible cardiogenic brain infarction

          -  Definite lacunar infarction

          -  Prior ischemic stroke within 6 months

          -  Evidence of hemorrhagic brain infarction, epidural hematoma, intracerebral hematoma,
             or intraventricular hemorrhage

          -  Severe consciousness disturbances (semicoma to deep coma)

          -  Neurological signs clearing spontaneously

          -  Disability of 2 or more on mRS score before the index stroke aPTT being out of the
             normal range or 1.5 times longer than the pretreatment value

          -  If taking an oral anticoagulant, INR being 1.6 or more, or no INR data

          -  Treatment with urokinase, t-PA, heparin, ozagrel sodium, warfarin, or antiplatelet
             except for aspirin before enrollment

          -  Intravascular surgery, surgical operation, hyperbaric oxygen therapy, or hypothermia
             therapy before enrollment

          -  Serum creatinine &gt;1.5 mg/dL

          -  Severe hepatic or cardiac disorders, infectious disorders, dehydration, etc.

          -  Neoplasm

          -  Pregnancy

          -  Hypersensitivity to test drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takenori Yamaguchi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cerebral and Cardiovascular Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Takenori Yamaguchi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cerebral and Cardiovascular Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>EAST Study Office c/o National Cardiovascular Center</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Jin YJ, Mima T, Raicu V, Park KC, Shimizu K. Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. Neurosci Res. 2002 May;43(1):75-9.</citation>
    <PMID>12074843</PMID>
  </reference>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>May 12, 2008</last_update_submitted>
  <last_update_submitted_qc>May 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>Takenori Yamaguchi, M.D., President Emeritus</name_title>
    <organization>National Cardiovascular Center</organization>
  </responsible_party>
  <keyword>Free Radical Scavenger</keyword>
  <keyword>Selective Thrombin Inhibitor</keyword>
  <keyword>Acute ischemic stroke (nonlacunar and noncardioembolic)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Argatroban</mesh_term>
    <mesh_term>Phenylmethylpyrazolone</mesh_term>
    <mesh_term>Antipyrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

